March 26, 2024
Contact: William Lutz 202-785-5100

Supreme Court Known for the Overturn of Roe v. Wade Tackles Medication Abortion, but the Safety and Effectiveness of Mifepristone Is Not in Question

Washington, D.C. — The Institute for Women’s Policy Research’s President and CEO, Dr. Jamila K. Taylor, today issued the following statement as the Supreme Court hears oral arguments in a case that aims to restrict access to abortion by challenging the safety of mifepristone, the drug commonly used for medication abortion.

“Mifepristone has been used by millions of women over the last 20 years, and its safety and effectiveness have been well-documented. The drug has taken on even greater importance for women’s health since the Supreme Court overturned Roe v. Wade, and the far right has moved to block women’s access to health care at every turn. Concern is always warranted when this Court gets anywhere near women’s reproductive rights, but this case is simple: mifepristone is safe and effective, and any claim otherwise is not based on facts, medicine, or science.

“The overturn of Roe was just the first step in the far right’s relentless campaign to restrict women’s reproductive freedom. We always knew they would come for medication abortion, too. But conservatives seeking to block access to mifepristone are not concerned about women’s safety; they want to block all abortion options for women and prevent them from making their own reproductive decisions, even in their own homes.”

The Institute for Women’s Policy Research strives to win economic equity for all women and eliminate barriers to their full participation in society. As a leading national think tank, IWPR builds evidence to shape policies that grow women’s power and influence, close inequality gaps, and improve the economic well-being of families. Learn more at and follow us on Twitter.